Magazine article from our research archive:

The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets.(Health Economics)

Treating patients with intracerebral hemorrhage (ICH) using recombinant activated factor VII (rFVIIa) has been found to improve survival and functional outcome. To examine how the introduction of rFVIIa 80 [micro]g/kg as a treatment for ICH affects the budget of a health plan, a decision-analysis model was developed which considered both short-term hospitalization costs and long-term management of disability. Assuming a health plan enrollment of 1 million members and initial rFVIIa uptake of 50% in appropriate patients, the annual health plan cost may be expected to increase by $64,781 ($0.005 per-member per-month). With a 5% increase in uptake each year, the annual health ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!